Gabapentin and neuropathic pain

Pain Clinic

Volumn 11, Issue 1, 1998, Pages 5-32

  Novelli, Gian Paolo ^a   Trovati, Ferdinando ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Gabapentin; Neuropathic pain; Neuropsychiatric diseases

Indexed keywords

ANTICONVULSIVE AGENT; GABAPENTIN;

ATAXIA; CONFERENCE PAPER; DIPLOPIA; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; EPILEPSY; FATIGUE; HEADACHE; NAUSEA; NEUROPATHY; NYSTAGMUS; PAIN; RHINITIS; SOMNOLENCE; TREMOR; VERTIGO; VOMITING;

EID: 0031880640     PISSN: 01691112     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (242)

1. Rosner H, Rubin L, Kestenbaum A, Gabapentin adjunctive therapy in neuropathic pain states, Clin J Pain 12 (1), 56-8 (1996).
2. McQuay H, Carroll D, Jadad AR, Wiffen P, Moore A, Anticonvulsant drugs for management of pain: a systematic review, BMJ 311, 1047-52 (1995).
3. Smith DB, Mattson RH, Cramer JA et al.. Results of a nationwide Veterans Administration Cooperative Study comparing the efficacy and toxicity of carbamazepine, phenobarbital, phenytoin, and primidone, Epilepsia 28 (Suppl. 3), S50-S58 (1987).
4. Pedley TA, The challenge of intractable epilepsy, in: New Trends in Epilepsy Management: the Role of Gabapentin, Chadwick D (Ed.), pp. 3-12. Royal Society of Medicine Services, London (1993).
5. Homan RW, Miller B, The Veterans Administration Epilepsy Cooperative Study Group. Causes of treatment failure with antiepileptic drugs vary over time, Neurology 37, 1620-23 (1987).
6. Ramsay RE, Clinical efficacy and safety of gabapentin, Neurology 44 (Suppl. 5), S23-S30 (1994).
7. Patsalos PN, Phenobarbitone to gabapentin: a guide to 82 years of anti-epileptic drug pharmacokinetic interactions, Seizure 3 (3), 163-70 (1994).
8. Mattson RH, Current challenges in the treatment of epilepsy, Neurology 44 (Suppl. 5), S4-S9(1994).
9. Natsch S, Hekster YA, Keyser A, Deckers CL, Meinardi H, Renier WO, Newer anticonvulsant drugs: role of pharmacology, drug interactions and adverse reactions in drug choice, Drug Saf 17 (4), 228-40 (1997).
10. Hughes D, Cockerell OC, A cost minimization study comparing vigabatrin, lamotrigine and gabapentin for the treatment of intractable partial epilepsy, Seizure 5 (2), 89-95 (1996).
11. Upton N, Mechanisms of action of new antiepileptic drugs: rational design and serendipitous findings, Trends Pharmacol Sci 15 (12), 456-63 (1994).
12. Meldrum BS, Update on the mechanism of action of antiepileptic drugs, Epilepsia 37, S4-S11(1996).
13. Taylor CP, Emerging perspectives on the mechanism of action of gabapentin, Neurology 44 (6), S10-S16 (1994).
14. McLean MJ, Gabapentin, Epilepsia 36, S73-S86 (1995).
15. Schmidt B, Potential antiepileptic drugs: gabapentin, in: Antiepileptic Drugs, 3rd ed, Levy R, Mattson R, Meldrum B et al. (Eds), pp. 925-35. Raven Press, New York (1989).
16. Satzinger G, Antiepileptics from gamma-aminobutyric acid, Arzneimittelforschung 44 (3), 261-6 (1994).
17. Bartoszyk GD, Meyerson N, Reimann W, Satzinger G, von Hodenberg A, New anticonvulsant drugs. Gabapentin, in: Current Problems in Epilepsy, , Meldrum BS, Porter RJ (Eds), Vol. 4, pp. 147-63. John Libbey, London (1986).
18. 3H]gabapentin to a novel site in rat brain: autoradiographic studies, EurJ Pharmacol 244 (3), 303-9 (1993).
19. Taylor CP, Vartanian MG, Yuen P-W et al., Potent and stereospecific anticonvulsant activity of 3-isobutyl GABA relates to IH vitro binding at a novel site labeled by tritiated gabapentin, Epilepsy Res 14 (1), 11-5 (1993).
20. Field MJ, Oles RJ, Lewis AS, McCleary S, Hughes J, Singh L, Gabapentin (Neurontin) and S-(+)-3-isobutylgaba represent a novel class of selective antihyperalgesic agents, Br J Pharmacol 121 (8), 1513-22 (1997).
21. Su TZ, Lunney E, Campbell G, Oxender DL, Transport of gabapentin, a gamma-amino acid drug, by system L alpha-amino acid transporters: a comparative study in astrocytes, synaptosomes, and CHO cells, J Neurochem 64 (5), 2125-31 (1995).
22. 3H]gabapentin binding to a novel site in rat brain: homogenate binding studies, Eur J Pharmacol 244 (3), 293-301 (1993).
23. 3H]gabapentin may label a system-L-like neutral amino acid carrier in brain, Eur J Pharmacol 247 (3), 341-5 (1993).
24. 2+ channel, J Biol Chem 271 (10), 5768-76 (1996).
25. Rock DM, Kelly KM, Macdonald RL, Gabapentin actions on ligand- and voltage-gated responses in cultured rodent neurons, Epilepsy Res 16 (2), 89-98 (1993).
26. 2δ subunit in current stimulation and subunit interaction, Neuron 16, 431-40 (1996).
27. Isom LL, De Jongh KS, Catterall WA, Auxiliary subunits of voltage-gated ion channels, Neuron 12, 1183-94 (1994).
28. Taylor CP, Vartanian MG, Andruszkiewicz R et al., 3-Alkyl-GABA and 3-alkylglutamic acid analogues: two new classes of anticonvulsant agents, Epilepsy Res 11, 103-10 (1992).
29. Dissanayake VU, Gee NS, Brown JP, Woodruff GN, Spermine modulation of specific [3H]-gabapentin binding to the detergent-solubilized porcine cerebral cortex alpha 2 delta calcium channel subunit, Br J Pharmacol 120 (5), 833-40 (1997).
30. Welty DF, Schielke GP, Vartanian MG, Taylor CP, Gabapentin anticonvulsant action in rats: disequilibrium with peak drug concentrations in plasma and brain microdialysate, Epilepsy Res 16 (3), 175-81 (1993).
31. Wamil AW, McLean MJ, Limitation by gabapentin of high frequency action potential firing by mouse central neurons in cell culture., Epilepsy Res 17 (1), 1-11 (1994).
32. Taylor CP, The anticonvulsant lamotrigine blocks sodium currents from alpha-subunits of rat brain Na+ channels in a voltage-dependent manner, but gabapentin does not, Abstract, Soc Neurosci Abst 19, 1631 (1993).
33. Löscher W, Hönach D, Taylor CP, Gabapentin increases aminooxyacetic acid-induced GABA accumulation in several regions of rat brain, Neurosci Lett 128 (2), 150-4 (1991).
34. Kocsis JD, Honmou O, Gabapentin increases GABA-induced depolarization in rat neonatal optic nerve, Neurosci Lett 169 (1-2), 181-4 (1994).
35. Honmou O, Kocsis JD, Richerson GB, Gabapentin potentiates the conductance increase induced by nipecotic acid in CA1 pyramidal neurons in vitro, Epilepsy Res 20 (3), 193-202 (1995).
36. Honmou O, Oyelese AA, Kocsis JD, The anticonvulsant gabapentin enhances promoted release of GABA in hippocampus: a field potential analysis, Brain Res 692 (1-2), 273-7 (1995).
37. Petroff OAC, Rothman DL, Behar KL, Lamoureux D, Mattson RH, The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy, Ann Neurol 39(1), 95-9 (1996).
38. Götz E, Feuerstein TJ, Lais A et al., Effects of gabapentin on release of gamma-aminobutyric acid from slices of rat neostriatum, Arzneimittelforschung/Drug Research 43(6), 636-8 (1993).
39. Reimann W, Inhibition by GABA, baclofen and gabapentin of dopamine release from rabbit caudate nucleus: are there common or different sites of action? Eur J Pharmacol 94 (3-4), 341-4 (1983).
40. Schlicker E, Gabapentin decreases monoamine release without affecting acetylcholine release in the brain, Arzneimittelforschung 35 (9), 1347-9 (1985).
41. Young LT, Robb JC, Patelis-Siotis I, MacDonald C, Joffe RT, Acute treatment of bipolar depression with gabapentin, Biol Psychiatry 42 (9), 851-3 (1997).
42. Ben-Menachem E, Persson LI, Hedner T, Selected CSF biochemistry and gabapentin concentrations in the CSF and plasma in patients with partial seizures after a single oral dose of gabapentin, Epilepsy Res 11 (1), 45-9 (1992).
43. Singh L, Field MJ, Ferris P, Hunter JC, Oles RJ, Williams RG, Woodruff GN, The antiepileptic agent gabapentin (Neurontin) possesses anxiolytic-like and antinociceptive actions that are reversed by D-serine, Psychopharmacology (Berl) 127 (1), 1-9 (1996).
44. Shimoyama N, Shimoyama M, Davis AM, Inturrisi CE, Elliott KJ, Spinal gabapentin is antinociceptive in the rat formalin test, Neurosci Lett 222 (1), 65-7 (1997).
45. McLean MJ, Clinical pharmacokinetics of gabapentin, Neurology 44 (6), S17-S22 (1994).
46. Richens A, Clinical pharmacokinetics of gabapentin, in: New Trends in Epilepsy Management: the Role of Gabapentin, Chadwick D (Ed.), pp. 41-6. Royal Society of Medicine Services, London (1993).
47. Stewart BH, Kugler AR, Thompson PR et al., A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma, Pharm Res 10 (2), 276-81 (1993).
48. Vollmer KO, Anhut H, Thomann P, Wagner F, Jähnchen D, Pharmacokinetic model and absolute bioavailability of the new anticonvulsant gabapentin, Adv Epileptol 17, 209-11 (1989).
49. Elwes RDC, Binnie CD, Clinical pharmacokinetics of newer antiepileptic drugs. Lamotrigine, vigabatrin, gabapentin and oxcarbazepine, Clin Pharmacokinet 30 (6), 403-15 (1996).
50. Vollmer KO, von Hodenberg A, Kölle EU, Pharmacokinetics and metabolism of gabapentin in rat, dog and man, Arzneimittelforschung 36 (5), 830-9 (1986).
51. Vollmer KO, Türck D, Bockbrader HN, Busch JA, Chang T, Summary of Neurontin (gabapentin) clinical pharmacokinetics, Abstract, Epilepsia 33 (Suppl. 3), 77 (1992).
52. Hengy H, Kölle EU, Determination of gabapentin in plasma and urine by high-performance liquid chromatography and pre-column labelling for ultraviolet detection, J Chromatogr 341 (2), 473-8 (1985).
53. Allen E, Jawad S, Wrae S, Richens A, Does the anticonvulsant gabapentin lack enzyme inducing properties? Abstract, in: Proc of 17th International Epilepsy Congress. Jerusalem (1987).
54. Hahn M, Gildemeister OS, Krauss GL, Pepe JA, Lambrecht RW, Donohue S, Bonkovsky HL, Effects of new anticonvulsant medications on porphyrin synthesis in cultured liver cells: potential implications for patients with acute porphyria, Neurology 49 (1), 97-106 (1997).
55. Comstock TI, Sica DA, Bockbrader HN, Underwood BA, Sedman AJ. Gabapentin pharmacokinetics in subjects with various degrees of renal function, Abstract, J Clin Pharmacol 30, 862 (1990).
56. Boyd RA, Brockbrader HN, Türck D, Sedman AJ, Posvar EL, Effect of subject age on the single dose pharmacokinetics of orally administered gabapentin (CI-945), Abstract, Pharmaceutical Research 7 (Suppl.), S215 (1990).
57. Bernus I, Dickinson RG, Hooper WD, Eadie MJ, Anticonvulsant therapy in aged patients. Clinical pharmacokinetic considerations, Drugs Aging 10 (4), 278-89 (1997).
58. Parke-Davis, Gabapentin Prescribing Informations. Morris Plains, NJ, USA (1994).
59. Hastelson CE, Keane WF, Türck D et al., Disposition of gabapentin (GAB) in hemodialysis (HD) patients, Abstract, J Clin Pharmacol 32, 751 (1992).
60. Hooper WD, Kavanagh MC, Herkes GK, Eadie MJ, Lack of a pharmacokinetic interaction between phenobarbitone and gabapentin, Br J Clin Pharmacol 31 (2), 171-4 (1991).
61. Graves NM, Holmes GB, Leppik IE, Rask C, Slavin M et al., Pharmacokinetics of gabapentin in patients treated with phenytoin, Abstract, Pharmacotherapy 9, 196 (1989).
62. Graves NM, Leppik IE, Wagner ML, Spencer MM, Erdmann GR, Effect of gabapentin on carbamazepine levels, Abstract, Epilepsia 31, 644-5 (1990).
63. Uthman BM, Hammond EJ, Wilder BJ, Absence of gabapentin and valproate interaction: an evoked potential and pharmacokinetic study, Abstract, Epilepsia 31, 645 (1990).
64. Busch JA, Radulovic LL, Bockbrader HN, Underwood BA, Sedman AJ et al., Effect of Maalox TC® on single-dose pharmacokinetics of gabapentin capsules in healthy subjects, Abstract, Pharm Res 9 (Suppl. 10), S315 (1992).
65. Goa KL, Sorkin EM, Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy, Drugs 46 (3), 409-27 (1993).
66. Leiderman DB, Gabapentin as add-on therapy for refractory partial epilepsy: results of five placebo-controlled trials, Epilepsia 35, S74-S76 (1994).
67. Marson AG, Kadir ZA, Chadwick DW, New antiepileptic drugs: a systematic review of their efficacy and tolerability, BMJ 313 (7066), 1169-74 (1996).
68. Abou-Khalil B, Shellenberger MK, Anhut H, Two open-label, multicenter studies on the safety and efficacy of gabapentin in patients with refractory epilepsy, Abstract, Epilepsia 33 (Suppl. 3), 77 (1992).
69. Bruni J, Gabapentin, Can J Neurol Sci 23 (4), S10-S12 (1996).
70. Browne T, Efficacy and safety of gabapentin, in: New Trends in Epilepsy Management: the Role of Gabapentin, Chadwick D (Ed.), pp. 47-58. Royal Society of Medicine Services, London (1993).
71. Sist TC, Filadora VA 2nd, Miner M, Lema M, Experience with gabapentin for neuropathic pain in the head and neck: report often cases, Reg Anesth 22 (5), 473-8 (1997).
72. Ojemann LM, Wilensky AJ, Temkin NR, Chmelir T, Ricker B et al., Long-term treatment with gabapentin for partial epilepsy, Epilepsy Res 13 (2), 159-65 (1992).
73. Dodrill CB, Wilensky AJ, Ojemann LM et al., Neuropsychological, mood, and psychosocial effects of gabapentin, Abstract, Epilepsia 33 (Suppl. 3), 117-8 (1992).
74. Leach JP, Girvan J, Paul A, Brodie MJ, Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy, J Neurol Neurosurg Psychiatry 62 (4), 372-6 (1997).
75. Childers MK, Holland D, Psychomotor agitation following gabapentin use in brain injury, Brain Inj 11 (7), 537-40 (1997).
76. Chudnow RS, Dewey RB Jr, Lawson CR, Choreoathetosis as a side effect of gabapentin therapy in severely neurologically impaired patients, Arch Neurol 54 (7), 910-2 (1997).
77. Reeves AL, So EL, Sharbrough FW, Krahn LE, Movement disorders associated with the use of gabapentin, Epilepsia 37 (10), 988-90 (1996).
78. Gil-Nagel A, Gapany S, Blesi K, Villanueva N, Bergen D, Incontinence during treatment with gabapentin, Neurology 48, 1467-71 (1997).
79. Handforth A, Treiman DM, Efficacy and tolerance of long-term, high-dose gabapentin: additional observations, Epilepsia 35, 1032-37 (1994).
80. Nissani M, Sanchez EA, Stuttering caused by gabapentin, (Letter), Ann Intern Med 126 (5), 410 (1997).
81. Picard C, Jonville-Bera AP, Billard C, Autret E, Alopecia associated with gabapentin: first case, Ann Pharmacother 31, 1260 (1997).
82. Gidal BE, Maly MM, Nemire RE, Haley K, Weight gain and gabapentin therapy, (Letter), Ann Pharmacother 29, 1048 (1995).
83. De Toledo JC, Toledo C, De Cerce J, Ramsay RE, Changes in body weight with chronic, high-dose gabapentin therapy, Ther Drug Monit 19, 394-6 (1997).
84. Fischer JH, Barr AN, Rogers SL, Fischer PA, Trudeau VL, Lack of serious toxicity following gabapentin overdose, Neurology 44 (5), 982-3 (1994).
85. Crawford P, Epilepsy and pregnancy: good management reduces the risks, Prof Care Mother Child 7 (1), 17-8 (1997).
86. Bartoszyk GD, The genetic animal model of reflex epilepsy in the Mongolian gerbil: differential efficacy of new anticonvulsive drugs and prototype antiepileptics, Pharmacol Res Commun 19 (6), 429-40 (1987).
87. Taylor CP, Mechanism of action of new antiepileptic drugs, in: New Trends in Epilepsy Management: the Role of Gabapentin, Chadwick D (Ed.), pp. 13-40. Royal Society of Medicine Services, London (1993).
88. Kondo T, Fromm GH, Schmidt B, Comparison of gabapentin with other antiepileptic and GABAergic drugs, Epilepsy Res 8 (3), 226-31 (1991).
89. Oles RJ, Singh L, Hughes G, Woodruff GN, The anticonvulsant action of gabapentin involves the glycine/NMDA receptor, Abstract, Soc Neurosci Abstr 16, 321-6 (1990).
90. Shimoyama M, Shimoyama N, Inturrisi CE, Elliott KJ, Gabapentin enhances the antinociceptive effects of spinal morphine in the rat tail-flick test, Pain 72 (3), 375-82 (1997).
91. Field MJ, Holloman EF, McCleary S, Hughes J, Singh L, Evaluation of gabapentin and S-(+)-3-isobutylgaba in a rat model of postoperative pain, J Pharmacol Exp Ther 282 (3), 1242-46 (1997).
92. Stanfa LC, Singh L, Williams RG, Dickenson AH, Gabapentin, ineffective in normal rats, markedly reduces C-fibre evoked responses after inflammation, Neuroreport 8 (3), 587-90 (1997).
93. Hunter JC, Gogas KR, Hedley LR, Jacobson LO, Kassotakis L, Thompson J, Fontana DJ, The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain, Eur J Pharmacol 324 (2-3), 153-60 (1997).
94. Hwang JH, Yaksh TL, Effect of subarachnoid gabapentin on tactile-evoked allodynia in a surgically induced neuropathic pain model in the rat, Reg Anesth 22 (3), 249-56 (1997).
95. Graves NM, Leppik IE, Antiepileptic medications in development. DICP, Ann Pharmacother 25 (9), 978-86 (1991).
96. Graves NM, Leppik IE, Advances in pharmacotherapy: recent developments in the treatment of epilepsy, J Clin Pharm Ther 18 (4), 227-42 (1993).
97. Cockerell OC, Johnson AL, Sander JW, Hart YM, Shorvon SD, Remission of epilepsy: results from the national general practice study of epilepsy, Lancet 346, 140-4 (1996).
98. The UK Gabapentin Study Group, Gabapentin in partial epilepsy, Lancet 335 (8698), 1114-7 (1990).
99. Sivenius J, Kalviainen R, Ylinen A, Riekkinen P, Double-blind study of Gabapentin in the treatment of partial seizures, Epilepsia 32 (4), 539-42 (1991).
100. Bruni J, Saunders M, Anhut H, Sauermann W, Efficacy and safety of gabapentin (Neurontin): a multicenter, placebo-controlled, double-blind study, Abstract, Neurology 41 (Suppl. 1), 330 (1991).
101. Anhut H, Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. The International Gabapentin Study Group, Epilepsia 35 (4), 795-801 (1994).
102. The US Gabapentin Study Group No. 5, Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study, Neurology 43 (11), 2292-98 (1993).
103. Bauer G, Bechinger D, Castell M, Deisenhammer E, Egli M et al., Gabapentin in the treatment of drug-resistant epileptic patients, Adv Epileptol 17, 219-21 (1989).
104. Garofalo E, Leiderman D, Chadwick D, Sauermann W, Pierce M, Gabapentin (Neurontin) add-on therapy in patients with generalized epilepsy, Abstract, Epilepsia 35 (Suppl. 7), 61 (1994).
105. Trudeau V, Myers S, LaMoreaux L, Anhut H, Garofalo E, Ebersole J, Gabapentin in naive childhood absence epilepsy: results from two double-blind, placebo-controlled, multicenter studies, J Child Neurol 11 (6), 470-5 (1996).
106. Anhut H, Greiner M, Mokel V et al., Gabapentin (Neurontin) as monotherapy in newly diagnosed patients with partial epilepsy, Epilepsia 36 (Suppl. 3), S119 (1995).
107. Garofalo E, Hayes A, Greeky C et al., Gabapentin (Neurontin) monotherapy in patients with medically refractory seizures: an open-label extension study, Epilepsia 36 (Suppl. 3), 5119-5120 (1995).
108. Bergey GK, Morris HH, Rosenfeld W, Blume WT, Penovich PE, Morrell MJ, Leiderman DB, Crockatt JG, LaMoreaux L, Garofalo E, Pierce M, Gabapentin monotherapy: I. An 8-day, double-blind, dose-controlled, multicenter study in hospitalized patients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 88/89, Neurology 49 (3), 739-45 (1997).
109. Beydoun A, Fischer J, Labar DR, Harden C, Cantrell D, Uthman BM, Sackellares JC, Abou-Khalil B, Ramsay RE, Hayes A, Greiner M, Garofalo E, Pierce M, Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 82/83, Neurology 49 (3), 746-52 (1997).
110. Welty DF, Schielke GP, Rothstein JD, Potential treatment of amyotrophic lateral sclerosis with gabapentin: a hypothesis, Ann Pharmacother 29 (11), 1164-67 (1995).
111. Miller RG et al., Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group, Neurology 47 (6), 1383-88 (1996).
112. Romano JG, Reduction of fasciculations in patients with amyotrophic lateral sclerosis with the use of gabapentin, Arch Neurol 53 (8), 716 (1996).
113. Williams DC, Periodic limb movements of sleep and the restless legs syndrome, Va Med Q 123 (4), 260-5 (1996).
114. Adler CH, Treatment of restless legs syndrome with gabapentin, Clin Neuropharmacol 20 (2), 148-51 (1997).
115. Cochran JW, Williams LB, Restless legs syndrome, JAMA 275 (3), 187 (1996).
116. Zoppi M, Editorial on the restless legs syndrome, The Pain Clinic (1998) (in press).
117. Kanthasamy AG, Vu TQ, Yun RJ, Truong DD, Antimyoclonic effect of gabapentin in a posthypoxic animal model of myoclonus, Eur J Pharmacol 297 (3), 219-24 (1996).
118. Patel J, Naritoku DK, Gabapentin for the treatment of hemifacial spasm, Clin Neuropharmacol 19 (2), 185-8 (1996).
119. Olson WL, Gruenthal M, Mueller ME, Olson WH, Gabapentin for parkinsonism: a double-blind, placebo-controlled, crossover trial, Am J Med 102 (1), 60-6 (1997).
120. McElroy SL, Soutullo CA, Keck PE Jr, Kmetz GF, A pilot trial of adjunctive gabapentin in the treatment of bipolar disorder, Ann Clin Psychiatry 9 (2), 99-103 (1997).
121. Stanton SP, Keck PE, McElroy SL, Treatment of acute mania with gabapentin, Am J Psychiatry 154 (2), 287 (1997).
122. Averbuch-Heller L, Leigh RJ, Medical treatments for abnormal eye movements: pharmacological, optical and immunological strategies, Aust N Z J Ophthalmol 25 (1), 7-13 (1997).
123. Averbuch-Heller L, Tusa RJ, Fuhry L, Rottach KG, Ganser GL, Heide W, Buttner U, Leigh RJ, A double-blind controlled study of gabapentin and baclofen as treatment for acquired nystagmus, Ann Neurol 41 (6), 818-25 (1997).
124. Gruenthal M, Mueller M, Olson WL, Priebe MM, Sherwood AM, Olson WH, Gabapentin for the treatment of spasticity in patients with spinal cord injury, Spinal Cord 35 (10), 686-9 (1997).
125. Priebe MM, Sherwood AM, Graves DE, Mueller M, Olson WH, Effectiveness of gabapentin in controlling spasticity: a quantitative study, Spinal Cord 35 (3), 171-5 (1997).
126. Mueller ME, Gruenthal M, Olson WL, Olson WH, Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis, Arch Phys Med Rehabil 78 (5), 521-4 (1997).
127. McGraw T, Kosek P, Erythromelalgia pain managed with gabapentin, Anesthesiology 86 (4), 988-90 (1997).
128. Samkoff LM, Daras M, Tuchman AJ, Koppel BS, Amelioration of refractory dysesthetic limb pain in multiple sclerosis by gabapentin, Neurology 49 (1), 304-5 (1997).
129. Coderre TJ, Katz J, Vaccarino AL, Melzack R, Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence, Pain 52, 259-85 (1993).
130. Fields HL, in: Core Curriculum for Professional Information in Pain, pp. 1-97. IASP Press (1991).
131. Zoppi M, unpublished observations.
132. Wall PD, Gutnick M, Ongoing activity in peripheral nerves. I. The physiology and pharmacology of impulses originating in a neuroma, Exp Neurol 43, 580 (1974).
133. Devor M, The pathophysiology of damaged peripheral nerves, in: Textbook of Pain, 3rd ed, Wall PD, Melzack R (Eds), pp. 79-100. Churchill Livingston, Edimborough (1994).
134. Calvin WH, Howe JF, Loeser JD, Ectopic repetitive firing in focally demyelinated axons and some implications for trigeminal neuralgia, in: Pain in the Trigeminal Region, Anderson D, Matthews B (Eds). Elsevier, Amsterdam (1977).
135. Kirk EJ, Impulses in dorsal spinal nerve rootlets in cats and rabbits arising from dorsal root ganglia isolated from the periphery, J Comparative Neurology 2, 165-76 (1974).
136. Burchiel KJ, Ectopic impulse generation in focally demyelinated trigeminal nerve, Exp Neurol 73, 345 (1981).
137. Raymond SA, Effects of nerve impulses on threshold of frog sciatic nerve fibers, J Physiology (Lond) 290, 273-303 (1979).
138. Calvin WH, Devor M, Howe J, Can neuralgias arise from minor demyelination? Spontaneous firing, mechanosensitivity and afterdischarge from conducting axons, Exp Neural 75, 755-63 (1982).
139. Granit R, Skoglund CR, Facilitation, inhibition and depression at the "artificial synapse" formed by the cut end of a mammalian nerve, J Physiology (Lond) 103, 435 (1945).
140. Seltzer Z, Devor M, Ephaptic transmission in chronically damaged peripheral nerves, Neurology 29, 1061 (1979).
141. Mayer ML, James MH, Russell RJ, Kelly JS, Pasternak CA, Changes in excitability induced by herpes simplex viruses in rat dorsal root ganglion neurons, J Neurosci 6, 391-402 (1986).
142. Jänig W, Activation of afferent fibers ending in an old neuroma by sympathetic stimulation in the rat, Neurosci Lett 111, 309-14 (1990).
143. Yamamoto T, Yaksh TL, Effects of colchicine applied to the peripheral nerve on the thermal hyperalgesia evoked with chronic nerve constriction, Pain 55, 227-33 (1993).
144. Loeser JD, Ward AA Jr, Some effects of deafferentation on neurons of the cat spinal cord, Arch Neurol 17, 629 (1967).
145. Basbaum AI, Wall PD, Chronic changes in the responses of cells in adult dorsal horn following partial deafferentation: the appearance of responding cells in a previously non-responding region, Brain Res 116, 181-204 (1976).
146. Wall PD, Devor M, The effects of peripheral nerve injury on dorsal root potentials and transmission of afferent signals into the spinal cord, Brain Res 209, 95-111 (1981).
147. Sugimoto T, Bennett GJ, Kajander KC, Transsynaptic degeneration in the superficial dorsal horn after sciatic nerve injury: effects of a chronic constriction injury, transection and strychnine, Pain 42, 205-13 (1990).
148. Snow PJ, Wilson P, Denervation induced changes in somatotopic organization: the ineffective projections of afferent fibers and structural plasticity, in: Processing of Sensory Information in the Superficial Dorsal Horn of the Spinal Cord, Cervero F, Bennett GJ, Headley PM (Eds), pp. 285-306. Plenum Press, New York (1989).
149. Woolf CJ, Shortland P, Caggeshall RE, Peripheral nerve injury triggers central sprouting of myelinated afferents, Nature 355, 75-7 (1992).
150. Devor M, Wall PD, Plasticity in the spinal cord sensory map following peripheral nerve injury in rats, J Neurosci 1 (7), 679 (1981).
151. Bennett GJ, Kajander KC, Sahara Y, Iadarola MJ, Sugimoto T, Neurochemical and anatomical changes in the dorsal horn of rats with an experimental painful peripheral neuropathy, in: Processing of Sensory Information in the Superficial Dorsal Horn of the Spinal Cord, Cervero F, Bennett GJ, Headley PM (Eds), pp. 463-71. Plenum Press, New York (1989).
152. Woolf CJ, Evidence for a central component of post-injury pain hypersensitivity, Nature 306, 686-8 (1983).
153. McMahon SB, Wall PD, Receptive fields of rat lamina 1 projection cells move to incorporate a nearby region of injury, Pain 19, 235-47 (1984).
154. Cook AJ, Woolf CJ, Wall PD, McMahon SB, Dynamic receptive field plasticity in rat spinal cord dorsal horn following C primary afferent input. Nature 325, 151-3 (1987).
155. Woolf CJ, Wall PD, Relative effectiveness of C primary afferent fibers of different origins in evoking a prolonged facilitation of the flexor reflex in the rat, J Neurosci 6, 1433-42 (1986).
156. Gracely RH, Lynch SA, Bennett GJ, Painful neuropathy: altered central processing, manteined dynamically by peripheral input, Pain 51, 175-94 (1992).
157. Pockett S, Spinal cord synaptic plasticity and chronic pain, Anesth Analg 80, 173-9 (1995).
158. Chang MM, Leeman SE, Isolation of a sialogogic peptide from bovine hypothalamic tissue and its characterization as substance P, J Biol Chem 245, 4784-90 (1970).
159. Randic M, Miletic V, Effect of substance P in cat dorsal horn neurons activated by noxious stimuli, Brain Res 128, 164-9 (1977).
160. Moochala SM, Sawyno KJ, Hyperalgesia produced by intrathecal substance P and related peptides: desensitization and cross-desensitization, Br J Pharmacol 82, 381-8 (1984).
161. Saria A, Gamse R, Petermann J, Fischer JA, Theodorsson-Norheim E, Lundeberg JM, Simultaneous release of several tachykinins and calcitonin gene-related peptide from rat spinal cord, Neurosci Lett 63, 981-91 (1986).
162. Villar MJ, Wiesenfeld HZ, Xu XJ et al., Further studies on galanin-, substance P-, and CGRP-like immunoreactivities in primary sensory neurons and spinal cord; effects of dorsal rhizotomies and sciatic nerve lesions, Exp Neur 112, 29-39 (1991).
163. Curtis DR, Phillis JW, Watkins JC, The chemical excitation of spinal neurones by certain amino acids, J Physiology (Lond) 150, 656-82 (1960).
164. Coderre TJ, Melzack R, Central neural mediators of secondary hyperalgesia following heat injury in rats: neuropeptides and excitatory amino acids, Neurosci Lett 131, 71-4 (1991).
165. Wilcox GL, Excitatory neurotransmitters and pain, in: Pain Research and Clinical Management, Proc of the Vth World Congress on Pain, Bond MR et al. (Eds), Vol. 4, pp. 97-117. Elsevier, Amsterdam (1991).
166. Gerber G, Randic M, Partecipation of excitatory amino acid receptors in the slow excitatory synaptic transmission in the rat spinal dorsal horn in vitro, Neurosci Lett 106, 220-8 (1989).
167. Woolf CJ, Thompson SWN, The induction and manteinance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation: implications for the treatment of post-injury pain hypersensitivity states. Pain 44, 293-9 (1991).
168. Aanonsen LM, Wilcox GL, Phencyclidine selectively blocks a spinal action of N-methyl-D-aspartate in mice, Neurosci Lett 67, 191-7 (1986).
169. Gordh T, Kristensen JD, The NMDA receptor antagonist CPP abolishes neurogenic "wind up pain" after intrathecal administration in humans, Reg Anesth 17 (Suppl.), S82 (1992).
170. Garthwaite J, Charles SL, Chess-Williams R, Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intracellular messenger in the brain, Nature 326, 385-7 (1988).
171. Sanders KM, Ward SM, Nitric oxide as a mediator of non-adrenergic non-cholinergic neurotransmission, Am J Physiol 262, G379-G392 (1992).
172. Lowenstein CJ, Dinerman JL, Snyder SH, Nitric oxide: a physiological messenger, Ann Intern Med 120, 227-37 (1994).
173. Meller ST, Gebhart GF, Nitric oxide (NO) and nociceptive processing in the spinal cord, Pain 52, 127-36(1993).
174. Kitto KF, Haley JE, Wilcox JL, Involvement of nitric oxide in spinally mediated hyperalgesia in the mouse, Newosci Lett 148, 1-5 (1992).
175. Malmberg AB, Yaksh T, Spinal nitric oxide synthesis inhibition blocks NMDA-induced thermal hyperalgesia and produces antinociception in the formalin test in rats. Pain 54, 291-300 (1993).
176. Meller ST, Dykstra C, Gebhart GF, Acute thermal hyperalgesia in the rat is produced by activation of N-methyl-D-aspartate receptors and protein kinase C and production of nitric oxide, Neuroscience 71, 327-35 (1996).
177. Radakrishnan V, Yashpal K, Hui-Chan CW, Henry JL, Implication of a nitric oxide synthase mechanism in the action of substance P: L-NAME blocks thermal hyperalgesia induced by endogenous and exogenous substance P in the rat, Eur J Neurosci 7, 1920-25 (1995).
178. Uda R, Horiguchi S, Ito S, Hyodo M, Hayaishi O, Nociceptive effects induced by intrathecal administration of prostaglandin D2, E2, or F2 alpha to conscious mice, Brain Res 510, 26-32 (1990).
179. 2 and amino acids evoked by paw formalin injection: a microdialysis study in unanesthetized rats, J Neurosci 15, 2768 (1995).
180. Malmberg AB, Yaksh TL, Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxigenase inhibition, Science 257, 1276-79 (1992).
181. Mjellem-Joly N, Lund A, Berge OG, Hole K, Intrathecal co-administration of substance P and NMDA augments nociceptive responses in the formalin test, Pain 51, 195-8 (1992).
182. Randic M, Hecimoviec H, Ryu PD, Substance P modulates glutamate-induced currents in acutely isolated rat spinal dorsal horn neurones, Neurosci Lett 117, 74-80 (1990).
183. Coderre TJ, Contribution of protein kinase C to central sensitization and persistent pain following tissue injury, Neurosci Lett 140, 181-4 (1992).
184. 2+ block of NMDA-receptor channels as a mechanism of modulation, Nature 356, 521-3 (1992).
185. Hunt SP, Pini A, Evan G, Induction of c-Fos-like protein in spinal cord neurons following sensory stimulation, Nature 328, 632-4 (1987).
186. Hughes P, Dragunow M, Induction of immediate-early genes and the control of neurotransmitter-regulated gene expression within the nervous system, Pharmacol Rev 47, 133-78 (1995).
187. Zimmermann M, Immediate-early genes in the nervous system - molecular steps in hyperalgesia and chronic pain? in: New Trends in Referred Pain and Hyperalgesia, Vecchiet L, Albe-Fessard D, Lindblom U (Eds), pp. 119-26. Elsevier, Amsterdam (1993).
188. Lerea LS, Butler LS, McNamara JO, NMDA and non-NMDA receptor-mediated increase of c-Fos mRNA in dentate gyrus neurons involves calcium influx via different routes, J Neurosci 12, 2973-81 (1992).
189. Kehl LJ, Gogas KR, Lichtblau L, Pollock CH, Mayes M, Basbaum AI, Wilcox GL, The NMDA antagonist MK801 reduces noxious stimulus-evoked Fos expression in the spinal cord dorsal horn, in: Pain Research and Clinical Management, Proc of the VIth World Congress on Pain, Bond MR et al. (Eds), Vol. 4, pp. 307-11. Elsevier, Amsterdam (1991).
190. Presley RW, Menetrey D, Levine JD, Basbaum AI, Systemic morphine suppresses noxious stimulus-evoked Fos protein-like immunoreactivity in the rat spinal cord, J Neurosci 10, 323-35 (1990).
191. Naranjo JR, Mellstrom B, Achaval M, Sassone-Corsi P, Molecular pathways of pain: Fos/Jun-mediated activation of a non canonical AP-1 site in the prodynorphin gene, Neuron 6, 607-17 (1991).
192. Watkins LR, Martin D, Ulrich P, Tracey KJ, Maier SF, Evidence for the involvement of spinal cord glia in subcutaneous formalin induced hyperalgesia in the rat, Pain 71, 225-35 (1997).
193. Diaz A, Dickenson AH, Blockade of spinal N- and P-type, but not L-type,
194. Malmberg AB, Yaksh TL, Voltage-sensitive calcium channels in spinal nociceptive processing: blockade of N- and P-type channels inhibits formalin-induced nociception, J Neurosci 14, 4882-90 (1994).
195. Moncada S, Ferreira SH, Vane JR, in: Inflammation, Handbook of Experimental Pharmacology, Vane JR, Ferreira SH (Eds), pp. 588-90. Springer-Verlag, Berlin (1979).
196. Yaksh TL, in: Acetylsalicilic Acid: New Uses for an Old Drug, Barett HJM, Hirsh J, Mustard JF (Eds), pp. 137-51. Raven, New York (1982).
197. Eisenach JC, Aspirin, the miracle drug: spinally, too? Anesthesiology 79, 211-3 (1993).
198. Malmberg AB, Yaksh TL, Pharmacology of the spinal action of ketorolac, morphine, ST 91, U50488H and L-PIA on the formalin test and an isobolographic analysis of the NSAID interaction, Anesthesiology 79, 270-81 (1993).
199. Max MB, Schafer SC, Culnane M, Dubner R, Gracely RH, Association of pain relief with drug side-effects in postherpetic neuralgia: a single-dose study of clonidine, codeine, ibuprofen and placebo, Clin Pharmacol Ther 43, 363 (1988).
200. Arner S, Myerson B, Opioids in neuropathic pain, Pain Digest 3, 15 (1993).
201. Dickenson AH, Sullivan AF, Subcutaneous formalin-induced activity of dorsal horn neurones in the rat: differential response to an intrathecal opiate administered pre- or post-formalin, Pain 30, 349-60 (1987).
202. Arner S, Myerson BA, Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain, Pain 33, 11-23 (1988).
203. Portenoy RK, Foley KM, Inturrisi C, The nature of opioid responsiveness and its implications for neuropathic pain. New hypotheses derived from studies of opioid infusions, Pain 43, 273-86 (1990).
204. Mao J, Price DD, Mayer DJ, Thermal hyperalgesia in association with the development of morphine tolerance in rats: roles of excitatory amino acid receptors and protein kinase C, J Neurosci 14, 2301-12 (1994).
205. Mayer DJ, Mao J, Price DD, The development of morphine tolerance and dipendence is associated with translocation of protein kinase C, Pain 61, 365-74 (1995).
206. Kolesnikov YA, Pick CJ, Ciszewska G, Pasternak GW, Blockade of tolerance to morphine but not to κ opioids by a nitric oxide synthase inhibitor, Proc Natl Acad Sci USA 90, 5162-6 (1993).
207. Paoli F, Darcourt G, Cossa P, Note preliminaire sur l'action de l'imipramine dans les états douloureux, Révue Neurologique 102, 503-4 (1960).
208. Woodforde JM et al. Treatment of post-herpetic neuralgia, Med J Aust 2, 869 (1965).
209. Max M, Antidepressants as analgesics, in: Pharmacological Approaches to the Treatment of Chronic Pain: New Concepts and Critical Issues, Fields HL, Liebeskind JC (Eds), pp. 229-46. IASP Press, Seattle (1994).
210. Watson CPN, Chpman M, Reed K, Evans RJ, Birkett N, Amitriptyline versus maprotiline in postherpetic neuralgia: a randomized, double blind, crossover trial, Pain 48, 29-36 (1992).
211. Killian JM, Fromm GH, Carbamazepine in the treatment of neuralgia. Use of sideeffects, Arch Neurol 19, 129 (1968).
212. Yaari Y, Devor M, Phenytoin suppresses spontaneous ectopic discharge in rat sciatic nerve neuromas, Neurosci Lett 58, 117-22 (1985).
213. Burchiel KJ, Carbamazepine inhibits spontaneous activity in experimental neuromas, Exp Neurol 102, 249-53 (1988).
214. Dejgard A, Peterson P, Kastrup J, Mexiletine for treatment of chronic painful diabetic neuropathy, Lancet 29, 9-11 (1988).
215. Chabal C, Jacobson L, Mariano A, Chaney E, Britell CW, The use of oral mexiletine for the treatment of pain after peripheral nerve injury, Anesthesiology 76, 513-7 (1992).
216. Boas RA et al., Analgesic responses to i.v. lignocaine, Br J Anaesth 54, 501-5 (1982).
217. Rowbotham MC, Risner LM, Fields HL, Both intravenous lidocaine and morphine reduce the pain of post-herpetic neuralgia, Neurology 41, 1024-28 (1991).
218. Marchettini P, Lacerenza M, Marangoni C, Pellegata G, Sotgiu ML, Smirne S, Lidocaine test in neuralgia, Pain 48, 377-82 (1992).
219. Coventry DM, Todd G, Epidural clonidine in lower limb deafferentation pain, Anesth Analg 69, 424-5 (1989).
220. Davis KD et al., Topical application of clonidine relieves hyperalgesia in patients with simpathetically manteined pain, Pain 41, 309-17 (1991).
221. 2-adrenoceptor agonists clonidine and dexmedetomidine on the prevention and treatment of experimental neuropathic pain, Anesth Analg 77, 104-9 (1993).
222. Yamamoto T, Nozaki-Taguchi N, Clonidine, but not morphine, delays the development of thermal hyperesthesia induced by sciatic nerve constriction injury in the rat, Anesthesiology 85, 835-45 (1996).
223. Taub A, Releief of post herpetic neuralgia with psychotropic drugs, J Neurosurg 39, 235-9 (1973).
224. Davis JL et al., Peripheral diabetic neuropathy treated with amitriptyline and fluphenazine, JAMA 238, 2291 (1977).
225. Sigwald J, Hebert H, Quetin A, The treatment of herpes and post-herpetic pain (and other resistant forms of pain) with phenotiazine derivatives, Semaine des Hopitaux de Paris 33, 1137 (1957).
226. Logan TP, Persistent phantom limb pain: dramatic response to chlorpromazine, South Med J 76, 1585 (1983).
227. Arner S, Intravenous phentolamine test: diagnostic and prognostic use in reflex sympathetic dystrophy, Pain 46, 17-22 (1991).
228. Raja SN, Treede R-D, Davis KD, Campbell JN, Systemic alpha-adrenergic blockade with phentolamine: a diagnostic test for sympathetically mantained pain, Anesthesiology 74, 691-8 (1991).
229. Hannington-Kiff JG, Intravenous regional sympathetic block with guanethidine, Lancet 1, 1019-29 (1974).
230. Parris WCV, Perspectives of chronic pain management: present and future, Pain Digest 6, 67-70 (1996).
231. Rosenberg JM, Harrell C, Ristic H, Werner RA, Michael de Rosayro A, The effect of gabapentin on neuropathic pain, Clin J Pain 13 (3), 251-5 (1997).
232. Mathew NT, Lucker C, Gabapentin in migraine prophylaxis: a preliminary open label study, Neurology 46, 9004 (1996).
233. Mellick GA, Mellick LB, Gabapentin in the management of reflex sympathetic dystrophy, J Pain Symptom Manage 10 (4), 265-6 (1995).
234. Mellick GA, Mellick LB, Reflex sympathetic dystrophy treated with gabapentin, Arch Phys Med Rehabil 78 (1), 98-105 (1997).
235. Mackin GA, Medical and pharmacologic management of upper extremity neuropathic pain syndromes, J Hand Ther 10 (2), 96-109 (1997).
236. Segal AZ, Rordorf G, Gabapentin as a novel treatment for postherpetic neuralgia, Neurology 46 (4), 1175-6 (1996).
237. Zapp JJ, Postpoliomyelitis pain treated with gabapentin, Am Fam Physician 53 (8), 2442 (1996).
238. Zoppi M, Novelli GP, Angelini C, A case of painful post-polio syndrome, The Pain Clinic 9, 343-7 (1997).
239. Zoppi M, Zamponi A, Pagni E, Buoncristiano U, A way to understand erythromelalgia, J Autonomic Nervous System 13, 85-9 (1983).
240. Zoppi M, Editorial: what is erythromelalgia? The Pain Clinic (1988) (in press).
241. Sist T, Filadora V, Miner M, Lema M, Gabapentin for idiopathic trigeminal neuralgia: report of two cases, Neurology 48 (5), 1467 (1997).
242. Mercadante S, Gabapentin in spinal cord injury pain, The Pain Clinic 10, 203-6 (1998).